Due to the lack of information on the binding of donanemab to pathological hallmarks in AD, we have performed an immunohistochemical study using post-mortem brain sections from patients with AD, Down syndrome and non-demented controls as well as AD mouse models 5XFAD, APP/PS1KI and TBA42. This evidence concerns the gene APP and Alzheimer disease.